Proportion of women in each treatment group who continue on original therapy with virologic suppression to less than 500 copies/ml at 34 weeks gestation (or the last viral load determination prior to delivery) [clinicaltrials_resource:a7f8787f248abf7756b65ddc142cbc5e]
Click here for more information about lamivudine
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
Proportion of women in each treatment group who continue on original therapy with virologic suppression to less than 500 copies/ml at 34 weeks gestation (or the last viral load determination prior to delivery) [clinicaltrials_resource:a7f8787f248abf7756b65ddc142cbc5e]
Click here for more information about lamivudine
Bio2RDF identifier
a7f8787f248abf7756b65ddc142cbc5e
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:a7f8787f248abf7756b65ddc142cbc5e
measure [clinicaltrials_vocabulary:measure]
Proportion of women in each tr ...... termination prior to delivery)
description
Click here for more information about lamivudine
identifier
clinicaltrials_resource:a7f8787f248abf7756b65ddc142cbc5e
title
Proportion of women in each tr ...... termination prior to delivery)
@en
type
label
Proportion of women in each tr ...... 8787f248abf7756b65ddc142cbc5e]
@en